Key Points
- CEO Omid Farokhzad sold 33,838 shares on Nov. 19 at an average price of $1.97 for about $66,660, reducing his stake by 2.66% to 1,238,230 shares, according to an SEC filing.
- Seer reported Q results showing EPS of ($0.32) — $0.01 ahead of estimates — and revenue of $4.12M, but remains deeply unprofitable (net margin -484.51%, negative ROE) with sell-side forecasts around -1.42 EPS for the year.
- Shares traded up 1.5% to $1.97 (market cap ~$109.9M), institutional investors own about 75% of the stock, and the consensus analyst rating is Sell.
Seer, Inc. (NASDAQ:SEER - Get Free Report) CFO David Horn sold 6,797 shares of the company's stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $1.97, for a total value of $13,390.09. Following the completion of the transaction, the chief financial officer directly owned 436,802 shares of the company's stock, valued at $860,499.94. The trade was a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Seer Trading Up 1.5%
SEER traded up $0.03 during trading on Friday, hitting $1.97. The company's stock had a trading volume of 166,159 shares, compared to its average volume of 148,170. The firm has a market capitalization of $109.90 million, a price-to-earnings ratio of -1.45 and a beta of 1.59. Seer, Inc. has a twelve month low of $1.62 and a twelve month high of $2.63. The business's fifty day simple moving average is $2.17 and its 200 day simple moving average is $2.12.
Seer (NASDAQ:SEER - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01. Seer had a negative return on equity of 25.88% and a negative net margin of 484.51%.The business had revenue of $4.12 million during the quarter, compared to the consensus estimate of $4.00 million. Seer has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Seer, Inc. will post -1.42 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Seer
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp grew its holdings in shares of Seer by 54.3% during the first quarter. OMERS ADMINISTRATION Corp now owns 76,200 shares of the company's stock worth $129,000 after buying an additional 26,819 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in Seer by 124.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 363,355 shares of the company's stock worth $614,000 after acquiring an additional 201,491 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Seer by 51.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,897 shares of the company's stock valued at $289,000 after acquiring an additional 58,173 shares in the last quarter. Jane Street Group LLC raised its holdings in Seer by 33.3% in the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company's stock valued at $430,000 after acquiring an additional 63,432 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Seer by 16.5% in the 2nd quarter. Geode Capital Management LLC now owns 509,727 shares of the company's stock worth $1,091,000 after purchasing an additional 72,265 shares in the last quarter. Institutional investors and hedge funds own 75.20% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Seer in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of "Sell".
Get Our Latest Research Report on Seer
Seer Company Profile
(
Get Free Report)
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
